Inflammatory and Nutritional Scoring System for Predicting Prognosis in Patients with Newly Diagnosed Multiple Myeloma

References

• van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410–427. doi:10.1016/s0140-6736(21)00135-5
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–2869. doi:10.1200/jco.2015.61.2267
   PubMed Web of Science ®Google Scholar
• Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–854. doi:10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420. doi:10.1200/jco.2005.04.242
   PubMed Web of Science ®Google Scholar
• Perrot A, Lauwers-Cances V, Tournay E, et al. Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. J Clin Oncol. 2019;37(19):1657–1665. doi:10.1200/jco.18.00776
   PubMed Web of Science ®Google Scholar
• Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009;84(12):1095–1110. doi:10.4065/mcp.2009.0603
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Pietrocola F, Kroemer G. Nutrition, inflammation and cancer. Nat Immunol. 2017;18(8):843–850. doi:10.1038/ni.3754
   PubMed Web of Science ®Google Scholar
• Caro J, Braunstein M, Williams L, et al. Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients. Leukemia. 2022;36(3):613–624. doi:10.1038/s41375-021-01506-9
   PubMed Web of Science ®Google Scholar
• Dosani T, Covut F, Beck R, Driscoll JJ, De lima M, Malek E. Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma. Blood Cancer J. 2017;7(6):e579. doi:10.1038/bcj.2017.60
   PubMedGoogle Scholar
• Romano A, Laura Parrinello N, Cerchione C, et al. The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents. Blood Cancer J. 2017;7(12):649. doi:10.1038/s41408-017-0019-6
   PubMedGoogle Scholar
• Romano A, Parrinello NL, Consoli ML, et al. Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. Ann Hematol. 2015;94(11):1875–1883. doi:10.1007/s00277-015-2462-4
   PubMed Web of Science ®Google Scholar
• Binder M, Rajkumar SV, Lacy MQ, et al. Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. Am J Hematol. 2019;94(3):306–311. doi:10.1002/ajh.25365
   Web of Science ®Google Scholar
• Okamoto S, Ureshino H, Kidoguchi K, et al. Clinical impact of the CONUT score in patients with multiple myeloma. Ann Hematol. 2020;99(1):113–119. doi:10.1007/s00277-019-03844-2
   PubMed Web of Science ®Google Scholar
• Zhou X, Lu Y, Xia J, Mao J, Wang J, Guo H. Association between baseline Controlling Nutritional Status score and clinical outcomes of patients with multiple myeloma. Cancer Biomark. 2021;32(1):65–71. doi:10.3233/cbm-210073
   PubMed Web of Science ®Google Scholar
• Kamiya T, Ito C, Fujita Y, et al. The prognostic value of the controlling nutritional status score in patients with multiple myeloma. Leuk Lymphoma. 2020;61(8):1894–1900. doi:10.1080/10428194.2020.1749608
   PubMed Web of Science ®Google Scholar
• Garzón Herazo JR, Muñoz Velandia OM, Solano JC, Molina Pimienta L, Figueroa Lemus WJ. The nutrition risk index is associated with bacteremia within 30 days after autologous stem cell transplantation in patients with multiple myeloma. Transpl Infect Dis. 2020;22(4):e13302. doi:10.1111/tid.13302
   Web of Science ®Google Scholar
• Jung SH, Yang DH, Ahn JS, et al. Decreased body mass index is associated with poor prognosis in patients with multiple myeloma. Ann Hematol. 2014;93(5):835–840. doi:10.1007/s00277-013-1977-9
   Web of Science ®Google Scholar
• Buzby GP, Mullen JL, Matthews DC, et al. Prognostic nutritional index in gastrointestinal surgery. Am J Surg. 1980;139(1):160–167. doi:10.1016/0002-9610(80)90246-9
   PubMed Web of Science ®Google Scholar
• Liang F, Dong XY, Tang GF, et al. Influence of prognostic nutritional index and controlling nutritional status on the prognosis of patients with multiple myeloma. Zhonghua Xue Ye Xue Za Zhi. 2021;42(4):332–337. Chinese. doi:10.3760/cma.j.issn.0253-2727.2021.04.011
   PubMedGoogle Scholar
• Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer. 2000;82(4):858–864. doi:10.1054/bjoc.1999.1012
   PubMed Web of Science ®Google Scholar
• Sandfeld-Paulsen B, Aggerholm-Pedersen N, Winther-Larsen A. Pretreatment albumin-to-alkaline phosphatase ratio is a prognostic marker in lung cancer patients: a registry-based study of 7077 lung cancer patients. Cancers. 2021;1(2):613. doi:10.3390/cancers1323613
   Google Scholar
• Wang Y, Xiong F, Yang J, et al. Decreased albumin-to-alkaline phosphatase ratio predicted poor survival of resectable gastric cancer patients. J Gastrointest Oncol. 2021;12(4):1338–1350. doi:10.21037/jgo-21-430
   PubMed Web of Science ®Google Scholar
• Bouillanne O, Morineau G, Dupont C, et al. Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005;82(4):777–783. doi:10.1093/ajcn/82.4.777
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503. doi:10.1016/s1470-2045(14)70263-3
   PubMed Web of Science ®Google Scholar
• Li WZ, Hua X, Lv SH, et al. A scoring system based on nutritional and inflammatory parameters to predict the efficacy of first-line chemotherapy and survival outcomes for de novo metastatic nasopharyngeal carcinoma. J Inflamm Res. 2021;14:817–828. doi:10.2147/jir.S296710
   PubMed Web of Science ®Google Scholar
• Wang N, Xi W, Lu S, et al. A novel inflammatory-nutritional prognostic scoring system for stage III gastric cancer patients with radical gastrectomy followed by adjuvant chemotherapy. Front Oncol. 2021;11:650562. doi:10.3389/fonc.2021.650562
   PubMed Web of Science ®Google Scholar
• Mao YS, Hao SJ, Zou CF, Xie ZB, Fu DL. Controlling Nutritional Status score is superior to Prognostic Nutritional Index score in predicting survival and complications in pancreatic ductal adenocarcinoma: a Chinese propensity score matching study. Br J Nutr. 2020;124(11):1190–1197. doi:10.1017/s0007114520002299
   Web of Science ®Google Scholar
• Lee S, Fujita K, Morishita T, et al. Prognostic utility of a geriatric nutritional risk index in combination with a comorbidity index in elderly patients with diffuse large B cell lymphoma. Br J Haematol. 2021;192(1):100–109. doi:10.1111/bjh.16743
   PubMed Web of Science ®Google Scholar
• Chen L, Bai P, Kong X, et al. Prognostic Nutritional Index (PNI) in patients with breast cancer treated with neoadjuvant chemotherapy as a useful prognostic indicator. Front Cell Dev Biol. 2021;9:656741. doi:10.3389/fcell.2021.656741
   Web of Science ®Google Scholar
• Wang KF, Chang BY, Chen XQ, et al. A prognostic model based on pretreatment platelet lymphocyte ratio for stage IE/IIE upper aerodigestive tract extranodal NK/T cell lymphoma, nasal type. Med Oncol. 2014;31(12):318. doi:10.1007/s12032-014-0318-8
   PubMed Web of Science ®Google Scholar
• Reddy JP, Hernandez M, Gunther JR, et al. Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. Br J Haematol. 2018;180(4):545–549. doi:10.1111/bjh.15054
   PubMed Web of Science ®Google Scholar
• Salman T, Kazaz SN, Varol U, et al. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for patients with neuroendocrine tumors: an Izmir oncology group study. Chemotherapy. 2016;61(6):281–286. doi:10.1159/000445045
   PubMed Web of Science ®Google Scholar
• Solmaz S, Uzun O, Acar C, et al. Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma? J Lab Physicians. 2018;10(4):363–369. doi:10.4103/jlp.Jlp_36_18
   Web of Science ®Google Scholar
• Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood. 1992;80(3):733–737. doi:10.1182/blood.V80.3.733.733
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Polloni C, et al. Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy. Clin Lymphoma Myeloma. 2008;8(5):294–299. doi:10.3816/CLM.2008.n.041
   Google Scholar
• Kim DS, Yu ES, Kang KW, et al. Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma. Korean J Intern Med. 2017;32(4):711–721. doi:10.3904/kjim.2016.054
   PubMed Web of Science ®Google Scholar
• Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69(4):491–497. doi:10.1016/s0149-2918(05)80001-3
   PubMed Web of Science ®Google Scholar
• Tian G, Li G, Guan L, Yang Y, Li N. Pretreatment albumin-to-alkaline phosphatase ratio as a prognostic indicator in solid cancers: a meta-analysis with trial sequential analysis. Int J Surg. 2020;81:66–73. doi:10.1016/j.ijsu.2020.07.024
   PubMed Web of Science ®Google Scholar
• An L, Yin WT, Sun DW. Albumin-to-alkaline phosphatase ratio as a promising indicator of prognosis in human cancers: is it possible? BMC Cancer. 2021;21(1):247. doi:10.1186/s12885-021-07921-6
   Web of Science ®Google Scholar
• Riveros C, Jazayeri SB, Chalfant V, Ahmed F, Bandyk M, Balaji KC. The Geriatric nutritional risk index predicts postoperative outcomes in bladder cancer: a propensity score-matched analysis. J Urol. 2022;207(4):797–804. doi:10.1097/ju.0000000000002342
   Web of Science ®Google Scholar
• Ruan GT, Zhang Q, Zhang X, et al. Geriatric Nutrition Risk Index: prognostic factor related to inflammation in elderly patients with cancer cachexia. J Cachexia Sarcopenia Muscle. 2021;12(6):1969–1982. doi:10.1002/jcsm.12800
   PubMed Web of Science ®Google Scholar
• Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. 2008;111(8):4039–4047. doi:10.1182/blood-2007-03-081018
   PubMed Web of Science ®Google Scholar
• Cejalvo MJ, Bustamante G, González E, et al. Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma. Ann Hematol. 2021;100(7):1769–1778. doi:10.1007/s00277-021-04529-5
   PubMed Web of Science ®Google Scholar
• Cook G, Royle KL, Pawlyn C, et al. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol. 2019;6(3):e154–e166. doi:10.1016/s2352-3026(18)30220-5
   PubMed Web of Science ®Google Scholar